Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of hypertension
Humanistic burden and health-related quality of life
11 evidence topics · 10 sources
Health-related quality of life and SF-6D utility in apparent treatment-resistant hypertension on four or more drug classes: MEPS 2000 to 2011
“We aimed to compare HrQoL measures in adults with apparent TRH (aTRH) and non-resistant hypertension among nationally representative US Medical Expenditure Panel Survey data pooled from 2000 to 2011.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“2501 (4.4%) met criteria for aTRH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Persons with aTRH, compared with non-resistant hypertension, had lower mean PCS scores (35.8 vs 43.2; P<0.0001), and utility (0.68 vs 0.74; P<0.0001), but similar MCS scores (49.1 vs 50.4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In multivariable-adjusted analyses, aTRH was associated with a 2.37 (95% CI 1.71 to 3.02) lower PCS score and 0.02 (95% CI 0.01 to 0.03) lower utility, compared with non-resistant hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, aTRH was associated with substantially lower HrQoL in physical functioning and health utility, but not in mental functioning, compared with non-resistant hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Proposed contributors to lower quality of life in treatment-resistant hypertension: review
“Recent evidence, although limited, suggests that TRH may also adversely affect health-related quality of life (HrQoL) and other patient-reported outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A number of recent studies focusing on both the general hypertensive population and those with TRH suggest that patient awareness of difficult-to-control blood pressure, chronically elevated blood pressure levels, and the use of aggressive medication regimens with attendant cumulative adverse effects may play significant roles.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SF-36 and SF-12 scores in hypertension compared with normotension: meta-analysis of 20 studies
“Most of the 20 studies selected for the systematic review identified lower quality of life in patients with hypertension, but they were very heterogeneous in regard to selection criteria and comparison groups, limiting their external validity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The meta-analysis identified lower scores in hypertensive patients for physical [-2.43; 95% confidence interval (CI) -4.77 to -0.08] and mental (-1.68; 95% CI -2.14 to -1.23) components.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Quality of life of individuals with hypertension is slightly worse than that of normotensive individuals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D index scores for hypertension and its cardiovascular complications: US catalogue from MEPS 2000 to 2002
“The nationally representative Medical Expenditure Panel Survey (MEPS) was pooled (2000−2002) to create a data set of 38,678 adults.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health state utilities used in the ICER model of aldosterone synthase inhibitors
| Health state | Utility or disutility |
|---|---|
| Hypertension alone | “Age-specific” |
| Acute myocardial infarction, disutility (3 months) | “-0.15” |
| Post-myocardial infarction, disutility | “-0.041” |
| Acute stroke, disutility (3 months) | “-0.19” |
| Post-stroke, disutility | “-0.052” |
| Coronary heart disease, disutility | “-0.034” |
| Heart failure, disutility | “-0.064” |
| End-stage kidney disease, disutility | “-0.170” |
EQ-5D-5L quality of life in 56 participants with resistant hypertension: RHYME-RCT
“A total of 56 patients with median age 61.5 [25th–75th percentile: 55.8–69.3] years (21.4% women) were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, no differences were observed in EQ-5D-5L index (0.81 [0.69–0.89] vs. 0.89 [0.73–1.00]; P = 0.18) and visual analogue scale score on general patient-perceived health (70 [60–80] vs. 70 [60–82]; P = 0.53) between the intervention-arm and the standard-of-care only-arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Irrespective of the intervention, independent positive predictors of the percentage adherence were patient age, EQ-5D-5L index score, BMQ-specific necessity score and concern score, whereas the total number of drugs prescribed was a negative predictor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment burden: patient input on pill burden, copays, and coverage barriers
Pill burden and nonadherence in resistant hypertension: review
“Reasons include adverse drug effects, pill burden, drug costs, long duration of treatment, and lack of communication from clinicians about the importance of medication adherence and persistence” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because adherence declines as the number of medications rises and the treatment regimen becomes more complex, poor adherence is a particular problem complicating the treatment of patients with RHT” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of prescribed antihypertensive drugs and biochemically confirmed nonadherence in 1348 participants
“We used high-performance liquid chromatography-tandem mass spectrometry of urine and serum to detect nonadherence and explored its association with the main demographic- and therapy-related factors in 1348 patients with hypertension from 2 European countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The rates of nonadherence to antihypertensive treatment were 41.6% and 31.5% in the UK and Czech populations, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Each increase in the number of antihypertensive medications led to 85% and 77% increase in nonadherence (P<0.001) in the UK and Czech populations, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We demonstrate that the number and class of prescribed antihypertensives are modifiable risk factors for biochemically confirmed nonadherence to blood pressure-lowering therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of medication nonadherence in apparent treatment-resistant hypertension: meta-analysis of 24 studies
“From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“By using a random effects model, the pooled prevalence of nonadherence was 31.2% (95% confidence interval = 20.2-44.7, I = 99.50) with nonadherence rates ranging from 3.3 to 86.1%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Findings indicate that medication nonadherence is a significant problem among aTRH patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Regimen simplification: single-pill compared with free-equivalent combination therapy, systematic review of 44 studies
“Following screening, 44 studies were included. The majority (18 of 23) of studies measuring adherence showed adherence was significantly improved in patients receiving SPCs versus FECs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SPC therapy leads to improved adherence and persistence compared with FEC therapy and may lead to better BP control in patients with hypertension.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote